Skip to content
★ Sign in to follow
카이

카이노스메드 Stock: price and insider trades · South Korea

KR·Mcap ₩35.6BHealth Care

No insider purchase over the last 90 days. The latest, by 이기섭, was filed 06 Feb 2023.

카이노스메드: what insiders have been doing

카이노스메드, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). 1 insider has disclosed 1 filing since 2 November 2025.

No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

No insider has bought 카이노스메드 shares on the open market in the past twelve months.

Compared with its exchange (2,655 companies, median 7 filings), a count of 1 filing is below the norm. The full history, which starts in 2021, counts 1 purchase against 39 sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.

Insider Decl.
47
Thresholds
n/a
Buy Volume
€210,741
1 ops. · all time
Sell Volume
€36M
39 ops. · all time
Fundamental score
Ranked 26,149 of 26,911 companies
11.8
score / 100
Value
11
Quality
13
FCF yld-17%
Earn yld-22%
EV/EBITDA·
ROE-108%
Gross mgn17%
Net mgn·
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

₩1,087
Analyst consensus
·
Income statement
Revenue₩1.2B
Gross profit₩199.8M17% margin
EBITDA-₩7.2B-611% margin
Net income-₩7.8B-664.4% margin
Valuation
Beta0.97
Balance sheet & cash
Market cap₩35.6B
Total debt₩147.3M
Free Cash Flow-₩6.2B
Debt / Equity1%
Profitability & ownership
ROE-107.7%
ROA-46.5%
% insiders28.4%
% institutions0.0%
Last declaration on 17 March 2026
Declarations47 total
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    0DART
    0KRXDART:20240618000099
  • ▼
    대표이사Executives
    0DART
    ShareKRXDART:20240613000007
  • ▼
    Executives
    €1.4Mest.0DART
    510,636 sharesKRXDART:20240613000006
  • ●
    Executives
    Executives(filed)
    0DART
  • ▼
    Executives
    €1.6Mest.0DART
    510,636 sharesKRXDART:20230620000052
  • ▼
    Executives
    €1.7Mest.0DART
    510,636 sharesKRXDART:20230609000049
  • ▼
    대표이사Executives(filed)
    0DART
    ShareKRXDART:20230411002363
  • ▼
    Executives(filed)
    €2.2Mest.0DART
    510,636 sharesKRXDART:20230411002396
  • ▼
    대표이사Executives(filed)
    0DART
    ShareKRXDART:20230407002666
  • ▼
    대표이사Executives(filed)
    0DART
    ShareKRXDART:20230406002098
  • ▼
    Executives(filed)
    €2.3Mest.0DART
    510,636 sharesKRXDART:20230406002070
  • ●
    Executives
    Executives(filed)
    0DART
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    대량보유자Executives(filed)
    €211kest.0DART
    52,421 sharesKRXDART:20230206000316
    Canonical exit: 7 May 2023 (T+90)
  • ▼
    Executives(filed)
    €1.4Mest.0DART
    510,636 sharesKRXDART:20220928000013
  • ▼
    Executives(filed)
    €1.4Mest.0DART
    510,636 sharesKRXDART:20220928000011
  • ▼
    Executives(filed)
    €1.4Mest.0DART
    510,636 sharesKRXDART:20220928000009
  • ▼
    Executives(filed)
    €1.4Mest.0DART
    510,636 sharesKRXDART:20220928000008
  • ▼
    Executives(filed)
    €1.4Mest.0DART
    510,636 sharesKRXDART:20220928000007
  • ▼
    Executives(filed)
    €2.3Mest.0DART
    510,636 sharesKRXDART:20220923000316
  • ▼
    대표이사Executives(filed)
    0DART
    ShareKRXDART:20220922000154
  • ▼
    대표이사Executives(filed)
    0DART
    ShareKRXDART:20220922000156
  • ▼
    Executives(filed)
    €2.3Mest.0DART
    510,636 sharesKRXDART:20220922000150
  • ▼
    대표이사Executives(filed)
    0DART
    ShareKRXDART:20220906000037

25 of 47 declarations

About 카이노스메드

Kainos Medicine operates in the healthcare and pharmaceutical sector, listed on the XKRX. The company focuses on developing innovative medical solutions.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations